August 13, 2022, Lund, Sweden – Exosomes are nanoparticles that enable human cells to communicate vital information with each other. They have potential to open a completely new field within diagnostics, as they can give us ‘status reports’ on organs such as the brain and heart, as well as give us vital information on tumor diseases, infectious diseases, pregnancy and stem cell conditions. EIC has announced that it granted AcouSort and its project partners SEK 26 million to develop an acoustofluidic thin-film actuated chip for exosome separation from blood. Of the SEK 26 million, SEK 12.2 million go directly to AcouSort, and the remainder of the funding is distributed to AcouSort’s partners Lund University, DTU, and Day One. The project will run for 36 months and is fully funded by the EU. [Read more…]
Pairing Cord Blood and Tissue Storage with Genetic Testing Services
One of the most prominent trends within the global cord blood banking industry is the pairing of cord blood and tissue storage with pre- and post-natal testing services, including genetic testing, genome sequencing, and metabolic screening services. The rise of this trend is driven by the ability of cord blood storage providers to offer complimentary services to existing clients, thereby expanding and diversifying their product portfolio.
As one cord blood executive recently told me, “They are looking to extend the relationship with the mother.” [Read more…]
Growth Rates & Trends within the Cord Blood Industry – Interview with Kenneth Harris
The cord blood banking industry is often surrounded by misleading metrics, making insights from experts especially valuable. In an interview with Kenneth Harris, Chief Advisor for CuraSense Advisors, we delve into his extensive knowledge of the field. The discussion covers global growth rates, key trends shaping the industry, geographic differences in opportunities, and more, providing a comprehensive look at this evolving sector.
Nucleus Biologics, Enabling Reproducible Science with David Sheehan (CEO)
In this interview with David Sheehan (CEO), we explore how Nucleus Biologics is revolutionizing the cell culture market through a concept known as “Precision Cell Culture.” The focus of Nucleus Biologics is to deliver superior cell culture products by leveraging a transparent, consistent and proven supply chain that eliminates variability for its customers. In addition to its novel Physiologix™ product line, Nucleus Biologics provides the highest quality Australia and New Zealand origin fetal bovine serum (FBS) available in the market with a goal to enable better lifesaving science.
With an estimated $28 billion lost per year to irreproducible biology research, it is clear that the market is overdue for disruption and Nucleus Biologics appears to be the company positioned to do it. In this interview, we explore Mr. Sheehan’s background, the disruptive nature of Nucleus Biologics, and his inspiring vision for the future. [Read more…]
New Super-Potent Topical Exosome Cosmetics Product, Distributed in UAE by Great Look Medical Supplies, to be Unveiled at Dubai Derma 2023 Conference March 1st- 3rd
ROCHESTER, NY and DUBAI, UAE, Feb. 17, 2023 – On March 1, Resiliélle Cosmetics, LLC and Regenerelle Biotherapeutics will unveil their new Resiliélle brand topical exosome cosmetics product manufactured by Regenerelle and exclusively distributed worldwide by Resiliélle. Resiliélle’s product will set a new standard for skin rejuvenation and lustrous hair. For optimal results, aesthetics professionals may use Resiliélle topically after microneedling or laser treatments. Resiliélle believes that the use of our topical exosome cosmetics will allow MedSpa, Dermatology and Plastic Surgery patients to use Resiliélle topical exosome cosmetics that have been developed to help patients to Leap Back In Time™ — At Any Age.™ [Read more…]
- « Previous Page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- …
- 340
- Next Page »